Brought to you by 
Roche acquires Cetus PCR rights for $300M plus $30M royalties
09 Feb 2000
Executive Summary
Hoffmann-La Roche (US subsidiary of Roche Holdings) has acquired full rights to the Polymerase Chain Reactor (PCR) technology from the Cetus Corporation. Hoffmann-La Roche will pay a cash value of $300 million and royalties of up to $30 million.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Alliance
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche acquires Cetus PCR rights for $300M plus $30M royalties
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice